A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2012-11-06

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1158/1535-7163.MCT-12-0336PMID 23136186PMCID PMC3546136
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• GPI-anchor remodeling: potential functions of GPI-anchors in intracellular trafficking and membrane dynamics.

  2012cited by this paper
• Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

  2012cited by this paper
• The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy

  2011cited by this paper
• Renal excretion of recombinant immunotoxins containing pseudomonas exotoxin.

  2011cited by this paper
• CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells

  2011cited by this paper
• Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes

  2011cited by this paper
• A guide to taming a toxin – recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer

  2011cited by this paper
• A Recombinant Immunotoxin Targeting CD22 With Low Immunogenicity, Low Nonspecific Toxicity, and High Antitumor Activity in Mice

  2010cited by this paper
• A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.

  2010cited by this paper
• Narrative Review: The Systemic Capillary Leak Syndrome

  2010cited by this paper
• Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

  2010cited by this paper
• Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

  2009cited by this paper
• Processing of Pseudomonas aeruginosa Exotoxin A Is Dispensable for Cell Intoxication

  2009cited by this paper
• A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

  2009influential reference
• Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

  2009cited by this paper
• Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors.

  2008cited by this paper
• Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers

  2007cited by this paper
• Elevated furin levels in human cystic fibrosis cells result in hypersusceptibility to exotoxin A-induced cytotoxicity.

  2007cited by this paper
• New Immunotoxins Targeting CD123, a Stem Cell Antigen on Acute Myeloid Leukemia Cells

  2007cited by this paper
• Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients1

  2006cited by this paper
• Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients

  2005influential reference
• HA22 (R490A) Is a Recombinant Immunotoxin with Increased Antitumor Activity without an Increase in Animal Toxicity

  2005cited by this paper
• Protein toxins: intracellular trafficking for targeted therapy

  2005cited by this paper
• Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.

  2005influential reference
• Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins.

  2004cited by this paper
• Recombinant immunotoxins in the treatment of cancer.

  2004cited by this paper
• Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas.

  2003cited by this paper
• Furin at the cutting edge: From protein traffic to embryogenesis and disease

  2002cited by this paper
• Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

  2002cited by this paper
• Medical physiology : a cellular and molecular approach

  2002cited by this paper
• Isolation of new anti‐CD30 scFvs from DNA‐immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin

  2001cited by this paper
• Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity.

  2001cited by this paper
• Inhibition of TNF-α Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2

  2000cited by this paper
• Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome.

  1999cited by this paper
• Improving antibody affinity by mimicking somatic hypermutation in vitro

  1999influential reference
• Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses.

  1998cited by this paper
• Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity.

  1998influential reference
• Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.

  1998cited by this paper
• Furin-mediated Cleavage of Pseudomonas Exotoxin-derived Chimeric Toxins*

  1997cited by this paper
• Characterization of vascular leak syndrome induced by the toxin component of Pseudomonas exotoxin-based immunotoxins and its potential inhibition with nonsteroidal anti-inflammatory drugs.

  1997cited by this paper
• Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.

  1996cited by this paper
• Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

  1996cited by this paper
• Treatment of advanced solid tumors with immunotoxin LMB–1: An antibody linked to Pseudomonas exotoxin

  1996cited by this paper
• Why toxins!

  1996cited by this paper
• Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor.

  1995cited by this paper
• Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity.

  1994influential reference
• Expression of mouse furin in a Chinese hamster cell resistant to Pseudomonas exotoxin A and viruses complements the genetic lesion.

  1993cited by this paper
• Increased cytotoxic activity of Pseudomonas exotoxin and two chimeric toxins ending in KDEL.

  1991cited by this paper
• Glomerular permselectivity: barrier function based on discrimination of molecular size and charge.

  1978cited by this paper

• Taming Bacterial Toxins into an Anticancer Platform.

  2025cites this paper
• Evaluating CAR-T cells from neurofibromatosis type 1 (NF1) patients for targeting AXL in malignant peripheral nerve sheath tumors associated with NF1

  2025cites this paper
• Neutrophil FcγRI expression as a determinant of oxidative responses in human blood

  2025cites this paper
• Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation

  2025cites this paper
• In vitro anti-tumor activities of a novel recombinant immunotoxin targeting differentially overexpressed Leucine-rich repeat-containing G-protein-coupled receptor 5 in cervical cancer

  2025cites this paper
• Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

  2024cites this paper
• Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Pseudomonas Exotoxin Catalytic Domain for Cancer Therapeutics

  2023cites this paper
• Enhanced cytotoxicity of a Pseudomonas Exotoxin A based immunotoxin against prostate cancer by addition of the endosomal escape enhancer SO1861

  2023influential citation
• Bacteria-derived chimeric toxins as potential anticancer agents

  2022cites this paper
• CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells

  2022cites this paper
• Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage

  2022cites this paper
• GPC1-targeted immunotoxins inhibit pancreatic tumor growth in mice via depletion of short-lived GPC1 and downregulation of Wnt signaling.

  2022cites this paper
• Pseudomonas Exotoxin-Based Immunotoxins: Over Three Decades of Efforts on Targeting Cancer Cells With the Toxin

  2021cites this paper
• An immunotoxin targeting Ebola virus glycoprotein inhibits Ebola virus production from infected cells

  2021cites this paper
• Targeting chemokines for acute lymphoblastic leukemia therapy

  2021cites this paper
• Immunotoxin IHP25-BT with low immunogenicity and off-target toxicity inhibits the growth and metastasis of trastuzumab-resistant tumor cells.

  2021cites this paper
• Mesothelin-Targeted Recombinant Immunotoxins for Solid Tumors

  2020cites this paper
• Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update

  2020cites this paper
• Immunotoxin SS1P is rapidly removed by proximal tubule cells of kidney, whose damage contributes to albumin loss in urine

  2020cites this paper
• Expert’s views and perspectives: an interview with distinguished investigator Dr. Ira Pastan at the National Cancer Institute at NIH

  2020cites this paper
• Application of therapeutic protein-based fusion toxins

  2019cites this paper
• Critical issues in the development of immunotoxins for anticancer therapy.

  2019cites this paper
• Inclusion of a Furin Cleavage Site Enhances Antitumor Efficacy against Colorectal Cancer Cells of Ribotoxin α-Sarcin- or RNase T1-Based Immunotoxins

  2019cites this paper
• A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells

  2019cites this paper
• Comparison between Fractionated Dose and Single Dose of Cu-64 Trastuzumab Therapy in the NCI-N87 Gastric Cancer Mouse Model

  2019cites this paper
• HER2-Specific Targeted Toxin DARPin-LoPE: Immunogenicity and Antitumor Effect on Intraperitoneal Ovarian Cancer Xenograft Model

  2019cites this paper
• Novel immunotherapeutic approaches for hepatocellular carcinoma treatment

  2019cites this paper
• Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models

  2019cites this paper
• Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.

  2019cites this paper
• Depletion of PD-1-positive cells ameliorates autoimmune disease

  2019cites this paper
• Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity

  2018cites this paper
• Construction and next-generation sequencing analysis of a large phage-displayed VNAR single-domain antibody library from six naïve nurse sharks

  2018cites this paper
• In Vitro Evaluation of Humanized/De-immunized Anti-PSMA Immunotoxins for the Treatment of Prostate Cancer.

  2018cites this paper
• Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity

  2018cites this paper
• Domain II of Pseudomonas Exotoxin Is Critical for Efficacy of Bolus Doses in a Xenograft Model of Acute Lymphoblastic Leukemia

  2018cites this paper
• Radioactive (90Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer

  2018cites this paper
• Preclinical development of anti-BCMA immunotoxins targeting multiple myeloma.

  2018cites this paper
• Glypicans as Cancer Therapeutic Targets.

  2018cites this paper
• Effects of EDC-PEI heparinization on allogeneic vascular antigens and inflammation levels via a rat abdominal aorta transplantation model

  2018influential citation
• Tumor-Shed Antigen Affects Antibody Tumor Targeting: Comparison of Two 89Zr-Labeled Antibodies Directed against Shed or Nonshed Antigens

  2018cites this paper
• Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.

  2018cites this paper
• Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II Engineering

  2018cites this paper
• A re-engineered immunotoxin shows promising preclinical activity in ovarian cancer

  2017cites this paper
• Clinical targeting recombinant immunotoxins for cancer therapy

  2017cites this paper
• CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases

  2017cites this paper
• Rational design of low immunogenic anti CD25 recombinant immunotoxin for T cell malignancies by elimination of T cell epitopes in PE38.

  2017cites this paper
• Recombinant Immunotoxin Therapy of Glioblastoma: Smart Design, Key Findings, and Specific Challenges

  2017cites this paper
• Antibody-Based Cancer Therapy: Successful Agents and Novel Approaches.

  2017cites this paper
• The proprotein convertase furin in tumour progression

  2017cites this paper
• Spheroids of HER2-Positive Breast Adenocarcinoma for Studying Anticancer Immunotoxins In Vitro

  2017cites this paper
• Generation and characterization of angiogenin mutants as improved effector domains for H22(scFv)-based cytolytic fusion proteins

  2017cites this paper
• Characterization and cytotoxic mechanisms of toxic and non-toxic type 2 ribosome-inactivating proteins

  2017cites this paper
• Future Horizons and New Target Class Opportunities

  2017cites this paper
• Herstellung und Charakterisierung von CD13-spezifischen Antikörperderivaten für die diagnostische und therapeutische Anwendung bei hämatologischen und soliden Krebserkrankungen

  2017cites this paper
• Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy

  2016cites this paper
• HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity.

  2016cites this paper
• Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer

  2016influential citation
• Wide Variability in the Time Required for Immunotoxins to Kill B Lineage Acute Lymphoblastic Leukemia Cells: Implications for Trial Design

  2016cites this paper
• CCR9 in cancer: oncogenic role and therapeutic targeting

  2016cites this paper
• Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A

  2016cites this paper
• Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors

  2016cites this paper
• Characterization of a re‐engineered, mesothelin‐targeted Pseudomonas exotoxin fusion protein for lung cancer therapy

  2016cites this paper
• Combination Radioimmunotherapy Approaches and Quantification of Immuno-PET

  2016cites this paper
• Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins

  2016cites this paper
• In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer

  2016cites this paper
• New Life for Immunotoxin Cancer Therapy

  2015cites this paper
• Ribosome-inactivating proteins and their immunotoxins for cancer therapy: insights into the mechanism of cell death

  2015influential citation
• CD30 Is a Potential Therapeutic Target in Malignant Mesothelioma

  2015influential citation
• Preclinical Immunogenicity Risk Assessement of Biotherapeutics

  2015cites this paper
• Tumor and organ uptake of (64)Cu-labeled MORAb-009 (amatuximab), an anti-mesothelin antibody, by PET imaging and biodistribution studies.

  2015cites this paper
• Challenges for Therapeutic Application of Pseudomonas Exotoxin-Based Immunotoxins

  2015cites this paper
• Anti-Mesothelin Nanobodies for Both Conventional and Nanoparticle-Based Biomedical Applications.

  2015cites this paper
• Advances in anticancer immunotoxin therapy.

  2015cites this paper
• [Idiopathic and secondary capillary leak syndromes: A systematic review of the literature].

  2015cites this paper
• α‐sarcin and RNase T1 based immunoconjugates: the role of intracellular trafficking in cytotoxic efficiency

  2015cites this paper
• Multiple antigenic polypeptide composed of heparanase B‑cell epitopes shrinks human hepatocellular carcinoma in mice.

  2015cites this paper
• Bortezomib Reduces Pre-Existing Antibodies to Recombinant Immunotoxins in Mice

  2015cites this paper
• Methylation-Associated Partial Down-Regulation of Mesothelin Causes Resistance to Anti-Mesothelin Immunotoxins in a Pancreatic Cancer Cell Line

  2015cites this paper
• Quantification of recombinant immunotoxin delivery to solid tumors allows for direct comparison of in vivo and in vitro results

  2015cites this paper
• to Recombinant Immunotoxins in Mice Bortezomib Reduces Pre-Existing Antibodies

  2015cites this paper
• Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.

  2015cites this paper
• Resistance to Immunotoxins in Cancer Therapy

  2015influential citation
• Large Molecule Therapeutics In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG 7787 in Pancreatic Cancer

  2014cites this paper
• Malignant Mesothelioma: Development to Therapy

  2014cites this paper
• Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer.

  2014cites this paper
• Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers

  2014cites this paper
• Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts

  2014cites this paper
• to Protein Therapeutics in Murine Hosts Tofacitinib Suppresses Antibody Responses

  2014cites this paper
• Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism.

  2014cites this paper
• Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting.

  2014cites this paper
• Translational immunotherapeutics: Chemoimmunotherapy for malignant pleural mesothelioma

  2014cites this paper
• Immune therapies for malignant mesothelioma

  2014cites this paper
• Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

  2014cites this paper
• Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

  2014cites this paper
• Antiviral Activity of a Single-Domain Antibody Immunotoxin Binding to Glycoprotein D of Herpes Simplex Virus 2

  2014cites this paper
• Large Molecule Therapeutics Ef fi cacy of RG 7787 , a Next-Generation Mesothelin-Targeted Immunotoxin , against Triple-Negative Breast and Gastric Cancers

  2014cites this paper
• In Vitro and In Vivo Activity of the Low-Immunogenic Antimesothelin Immunotoxin RG7787 in Pancreatic Cancer

  2014cites this paper
• Recombinant Immunotoxin Therapy of Solid Tumors: Challenges and Strategies.

  2013cites this paper
• Mesothelioma: closer to the target?

  2013cites this paper